Navigation Links
Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients
Date:8/1/2009

SAN FRANCISCO (August 1, 2009)Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

"Based on our initial data, the combination appears to be well tolerated and efficacious, though we'll have to wait and see the final results," says Hossein Borghaei, D.O., medical oncologist at Fox Chase, who led the trial.

Elderly patients are often excluded from clinical trials because researchers fear they will have trouble tolerating standard chemotherapy regimens. That leaves open the question of how best to treat these individuals who account for more than half of all NSCLC in the United States.

With that challenge in mind, Borghaei and colleagues designed a trial testing a combination of two molecularly targeted agents in patients 70 years or older. The team reasoned that a combination lacking standard cytotoxic agents may be better tolerated by these patients, potentially without comprising efficacy. "We looked for a regimen that had few side effects, would involve only targeted agents, and had a bit of a track record. This combination was a natural fit," Borghaei says. Several small phase II trials in younger NSCLC patients demonstrated that the combination had anti-tumor activity and a relatively favorable toxicity profile.

Thus far 21 elderly NSCLC patients have enrolled in the Fox Chase trial and 14 are evaluable for response. The median age of the 14 evaluable patients is 78, with a range of 71 to 84 years. Four patients have had partial responses with demonstrable tumor shrinkage and three patients had stable disease by RECIST criteria.

The combination appears safe and well tolerated in this patient population with the most commonly encountered toxicities of clinical relevance being high blood pressure, fatigue, loss of appetite and diarrhea.

"The observed activity of this regimen in this patient population suggests promise and therefore warrants continued investigation," Borghaei says. He also emphasizes that designing a clinical trial just for elderly patients is a novel approach, but one that should be used more in the future given the large proportion of NSCLC patients in this demographic group.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
2. Northstar Healthcare Announces Option to Purchase a 60% Interest in The Palladium for Surgery - Dallas
3. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
4. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
5. Kensey Nash Announces $25 Million Stock Repurchase Program
6. Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance
7. Flextronics Announces Redemption and Change of Control Repurchase Offer for Solectron 8.00% Senior Subordinated Notes and Planned Change of Control Repurchase Offer for Solectrons 0.50% Senior Convertible Notes
8. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
9. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
10. Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics
11. Governor Schwarzeneggers Mandatory Purchase of Private Health Insurance Doesnt Add Up for the Middle-Class, Says FTCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
Breaking Medicine Technology: